Richmond Pharmacology
Generated by Meeveem AI
"Leading UK clinical research organisation pioneering gene editing and early phase trials"
London
•51 - 250 Employees
•Contract Research
About Richmond Pharmacology
Richmond Pharmacology conducts early phase clinical trials for pharmaceutical and biotech companies. Specialising in first-in-human studies through proof-of-concept, the organisation has expertise in gene editing, RNA therapies, cardiovascular diseases, and rare conditions. Operating from Guy's Hospital in London, Richmond works with leading pharma companies to assess safety and efficacy of ground-breaking treatments. Founded in 2001, Richmond has completed over 500 clinical trials and made history as the first CRO to administer CRISPR-Cas9 gene therapy to humans. With over 310,000 registered volunteers and adaptive study designs meeting global regulatory requirements, Richmond enables faster marketing approvals for sponsors.
210
Team Members
2001
Founded
Contract Research
Sector
Hybrid
Work Environment
Our Vision
A world where ground-breaking therapies reach patients faster through precision clinical research that advances gene editing, rare disease treatments, and innovative medical science.
Our Mission
Advances drug development by conducting rigorous early phase clinical trials that enable pharmaceutical and biotech companies to bring safe, effective therapies to market with speed and scientific excellence.